Lucius Mirdametinib – Acheter en ligne
Lucius Mirdametinib – Acheter en ligne

Lucius Mirdametinib – Acheter en ligne

EUR 563.29

2,400+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

(Mirdametinib) MEK1 MEK2 ，

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
1mg*42 gelules/boite
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Catégorie : Marque :

Informations produit

Nom anglais
Mirdametinib
Nom générique
Mirdametinib

Caractéristiques

Spécification
1mg*42 gelules/boite
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Mirdametinib is the first and only therapy approved in the European Union for adults and children 2 years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Mécanisme d’action

Mirdametinib Mecanisme d action Mecanisme d action ，

Posologie

2 GOMEKLI 2 mg/m²， ， ， 28 21 GOMEKLI (2) 2.1 GOMEKLI GOMEKLI [ Precautions (5.1)] (EF)[ Precautions (5.2)] 2.2 GOMEKLI GOMEKLI GOMEKLI ，

Precautions

5 Precautions GOMEKLI ， ， ， ， GOMEKLI (5.1) GOMEKLI ， ， 3 ， GOMEKLI (5.2) ， ， GOMEKLI

Package Insert

Ingredients

11 GOMEKLI (R)-N-(2,3- )-3,4- -2-((2- -4- ) ) C16H14F3IN2O4， 482.20 g/mol ， 25°C 0.25 mg/mL，pH 7.2 pKa 7.96

Indications

Mirdametinib is the first and only therapy approved in the European Union for adults and children 2 years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Posologie

2 GOMEKLI 2 mg/m²， ， ， 28 21 GOMEKLI (2) 2.1 GOMEKLI GOMEKLI [ Precautions (5.1)] (EF)[ Precautions (5.2)] 2.2 GOMEKLI GOMEKLI GOMEKLI ，

Precautions

5 Precautions GOMEKLI ， ， ， ， GOMEKLI (5.1) GOMEKLI ， ， 3 ， GOMEKLI (5.2) ， ， GOMEKLI

Use in Pregnancy and Lactation

8.1 Mecanisme d action[ (12.1)] ，GOMEKLI - ， mirdametinib， - ， (BSA) 2 mg/m²， ， 2% 4% 15% 20%

Clinical Pharmacology

12 12.1 Mecanisme d action 1 2 (MEK1/2) MEK1/2 (ERK) ， MEK1 MEK2 ERK NF1 ， ERK ， 12.2 -

Pharmacology and Toxicology

13 13.1 6 rasH2 ， 5 mg/kg AUC ， 2 mg/m² 15 Ames ， 1 ， 28

Clinical Studies

6.1 ， ， Precautions Description ReNeu [ (14)] n=114 NF-106 n=19 [NCT-02096471] 133 75 58 GOMEKLI 28 21 GOMEKLI 2 mg/m²， ， GOMEKLI 133 ，62% ，38% ，12%

Avis produit (17)

Filtre : Tous les avis
4.8★★★★★
17 avis clients14 achats verifies
+o***e· 3周前
★★★★
+t***3· 1个月前
Achat verifie
★★★★★

Description

Indications

Mirdametinib is the first and only therapy approved in the European Union for adults and children 2 years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Mécanisme d’action

Mirdametinib Mecanisme d action Mecanisme d action ，

Posologie

2 GOMEKLI 2 mg/m²， ， ， 28 21 GOMEKLI (2) 2.1 GOMEKLI GOMEKLI [ Precautions (5.1)] (EF)[ Precautions (5.2)] 2.2 GOMEKLI GOMEKLI GOMEKLI ，

Precautions

5 Precautions GOMEKLI ， ， ， ， GOMEKLI (5.1) GOMEKLI ， ， 3 ， GOMEKLI (5.2) ， ， GOMEKLI